Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Virginia Health System, P.O. Box 801410, Charlottesville, Virginia 22908, USA.
J Clin Endocrinol Metab. 2012 Jul;97(7):E1208-12. doi: 10.1210/jc.2011-3455. Epub 2012 Apr 16.
Angiotensin II type 1 receptor (AT(1)R) tone restricts muscle microvascular blood volume (MBV) and decreases muscle insulin delivery and glucose use.
The objective of the study was to examine whether acute AT(1)R blockade alters microvascular perfusion in skeletal and cardiac muscle in humans.
The study was conducted at the General Clinical Research Center at the University of Virginia.
Eight overnight-fasted healthy young adults were studied thrice in random order. In study 1, each subject received candesartan (32 mg) orally at time 0. In study 2, each subject received placebo at time 0 and a 1 mU/min · kg euglycemic insulin clamp from time 240 to 360 min. In study 3, each subject received candesartan (32 mg) orally at time 0 and insulin infusion from 240 to 360 min. Forearm skeletal and cardiac muscle MBV, microvascular flow velocity, and microvascular blood flow (MBF) were determined at baseline and at 240 and 360 min.
Candesartan treatment acutely recruited microvasculature in both skeletal and cardiac muscle by significantly increasing MBV (P < 0.03 and P = 0.02, respectively) and MBF (P < 0.03 for both) without altering microvascular flow velocity. Insulin infusion significantly increased cardiac MBV (P = 0.02) and MBF (P < 0.02). Superimposing insulin infusion 4 h after candesartan ingestion did not further recruit microvasculature. Insulin-mediated whole-body glucose disposal did not differ with or without candesartan pretreatment.
Acute AT(1)R blockade with candesartan recruits skeletal as well as cardiac muscle microvasculature in healthy humans without altering insulin-mediated whole-body glucose disposal. This may contribute to the observed improvement in the cardiovascular outcomes in patients receiving prolonged treatment with AT(1)R blockers.
血管紧张素 II 型 1 型受体 (AT(1)R) 张力限制肌肉微血管血容量 (MBV),并降低肌肉胰岛素输送和葡萄糖利用。
本研究旨在探讨急性 AT(1)R 阻断是否会改变人体骨骼肌和心肌的微血管灌注。
该研究在弗吉尼亚大学综合临床研究中心进行。
8 名 overnight-fasted 健康年轻成年人以随机顺序进行了 3 次研究。在研究 1 中,每位受试者在 0 时口服坎地沙坦(32mg)。在研究 2 中,每位受试者在 0 时接受安慰剂,从 240 到 360 分钟给予 1mU/min·kg 正葡萄糖胰岛素钳夹。在研究 3 中,每位受试者在 0 时口服坎地沙坦(32mg),并在 240 到 360 分钟内输注胰岛素。基线和 240 及 360 分钟时测定前臂骨骼肌和心肌 MBV、微血管血流速度和微血管血流量 (MBF)。
坎地沙坦治疗可使骨骼肌和心肌的微血管迅速募集,MBV(P<0.03 和 P=0.02)和 MBF(两者均 P<0.03)显著增加,而微血管血流速度不变。胰岛素输注可显著增加心肌 MBV(P=0.02)和 MBF(P<0.02)。在坎地沙坦给药 4 小时后叠加胰岛素输注并未进一步募集微血管。有或没有坎地沙坦预处理,胰岛素介导的全身葡萄糖处置无差异。
坎地沙坦急性阻断 AT(1)R 受体可募集健康人体的骨骼肌和心肌微血管,而不改变胰岛素介导的全身葡萄糖处置。这可能有助于解释接受 AT(1)R 阻滞剂长期治疗的患者心血管结局的改善。